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Objective: The purpose of this study was to evaluate outcomes of patients treated by intentional coverage of accessory renal
artery (ARA) during endovascular abdominal aneurysm repair (EVAR).
Methods: The clinical data of 119 patients (110 male and nine female; mean age, 75 years) from a cohort of 811 patients
treated by EVAR from 1998 to 2009 was reviewed. Patients who had intentional coverage of at least one ARA (group A)
were compared with two control groups, which included patients with no ARA (group B) and those who had ARA
preserved during EVAR (group C). All three groups of patients were matched for age, gender, hypertension, and
preoperative estimated glomerular ﬁltration rate (eGFR). Paired pre- and postoperative computed tomography angiog-
raphy was analyzed for the presence and volume of kidney infarction. End points were changes in eGFR, chronic kidney
disease (CKD) stage, blood pressure measurements, presence and volume of kidney infarction, freedom from reinter-
vention, and endoleak.
Results: There were 42 patients in group A, 42 in group B, and 35 in group C. Demographics, cardiovascular risk factors,
and CKD classiﬁcation were similar in all three groups. Among patients in group A, 44 ARAs were intentionally covered
with ARAs originating from the proximal neck in 22 patients, the aneurysm sac in 20, and the iliac arteries in two. There
was one (1%) early death in the entire study. Early morbidity was similar in all three groups, including four patients (9%)
in group A, four (9%) in group B, and four (11%) in group C (P [ .9). Six (5%) patients had >25% decrease in eGFR,
including two who had ARA coverage. None of the patients required dialysis. After a mean follow-up of 37 months, there
were no differences in late renal function deterioration, changes in eGFR, CKD stage, or blood pressure measurements
among the three groups. Three of the 18 patients (17%) with ARA >3 mm arising from the aneurysm sac developed a type II
endoleak requiring coil embolization. Kidney infarction was noted in 28 patients (67%) in group A. Freedom from
reintervention at 2 years was similar in groups A (64%), B (80%), and C (96%; P [ .09).
Conclusions: Intentional ARA occlusion during EVAR was not associated with changes in renal function or blood pressure
measurements, even when performed in patients with more advanced renal dysfunction. Type II endoleak may result from
persistent outﬂow into large (>3 mm) ARAs that arise from the aneurysm sac. (J Vasc Surg 2013;58:1467-75.)Endovascular aortic aneurysm repair (EVAR) has
gained widespread acceptance as an alternative to treat
patients with abdominal aortic aneurysms (AAAs).1 Preop-
erative imaging is critical to plan the procedure and
adequately select patients on the basis of proximal and
distal landing zones, involvement of aortic side branches,
or presence of unusual arterial anatomy. Accessory renal
artery (ARA) is an anatomical variation found in 25% to
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repair, potentially decreasing rates of kidney infarction
and changes in renal function.6,7 The presence of an
ARA arising from the seal zone or aneurysm sac requires
coverage by the stent graft or coil embolization during
EVAR.
Given that EVAR has been associated with loss of renal
function from repeated doses of iodinated contrast and
catheter manipulations, ARA occlusion may further
contribute to renal function deterioration or changes in
blood pressure management. Prior reports indicate that
intentional coverage of ARAs during EVAR appears to be
safe.8-12 However, some of these studies have important
limitations, including lack of analysis of clinical, laboratory,
and anatomical data using standardized deﬁnitions, such as
renal function deterioration measured using changes in
estimated glomerular ﬁltration rate (eGFR) and chronic
kidney disease (CKD) stage. In addition, prior reports
have not included a control group comprised of patients
who had preservation of the entire kidney parenchyma
during EVAR.8-11 The purpose of this study was to eval-
uate outcomes of patients who had EVAR with intentional
ARA coverage using standardized clinical, laboratory,1467
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patients who had EVAR with total kidney parenchyma
preservation.
METHODS
Study design. The study was approved by the Institu-
tional Review Board of the Mayo Clinic. We retrospectively
reviewed the clinical data of 811 patients treated by EVAR
for AAAs from 1998 to 2009. From this cohort, 672
patients (83%) were considered for potential inclusion in
the study. One hundred thirty-nine patients (17%) were
excluded because of prior open or endovascular aortic
repair, solitary kidney, renal artery occlusive disease, CKD
stage V, or ruptured, inﬂammatory, infected, or complex
aortic aneurysms involving the main renal arteries or
mesenteric arteries. Patients who underwent simultaneous
renal artery revascularization by means of stenting for high-
grade renal artery stenosis were also excluded. Patients with
ARA >4 mm or solitary kidney were offered open repair
with preservation of ARAs.
All patients considered for inclusion in the study had
preoperative computed tomography angiography (CTA)
imaging using either a 16- or 64-multidetector CT scanner.
Two hundred patients (30%) had 230 ARAs identiﬁed by
preoperative CTA. No more than three ARAs were found
per patient. The overall incidence of right ARA was higher
than the left (125 vs 105; P ¼ .04). Age, gender, and
preoperative eGFR and National Kidney Foundation
CKD stage was utilized to identify case and control patients
for comparison of outcomes in one of three groups. Forty-
two patients who had intentional coverage of at least one
ARA (group A) were compared with two matched control
groups who had total kidney preservation, including
42 patients with no ARA (group B) and 35 patients with
preservation of ARA (group C).
End points. Primary end points were changes in the
eGFR and blood pressure measurements. Secondary end
points were morbidity and mortality, presence and volume
of kidney infarct, changes in the aneurysm sac (enlarge-
ment/shrinkage), endograft migration, endoleak, graft
patency, and patient survival reported according to the
Society of Vascular Surgery reporting standards for
EVAR.13 Type II endoleaks were analyzed to determine
their relation to patency of an ARA. The early post-
operative period was deﬁned as occurring within less than
30 days or during hospital stay.
Renal function assessment. Total serum creatinine
levels and eGFR were utilized to assess renal function.
The GFR was estimated for patients younger than 85 years
using the Modiﬁcation of Diet in Renal Disease equation
provided and recommended by the National Kidney
Disease Outcomes Quality Initiative from the National
Kidney Foundation.14 The Cockcroft-Gault equation was
applied to patients who were >85 years of age as an
alternative to the Modiﬁcation of Diet in Renal Disease
equation.15 Preoperative creatinine values and estimated
GFR were calculated using at least three separate mea-
surements within 6 months prior to the EVAR wheneverpossible. Patients were classiﬁed using eGFR in CKD stages
as outlined by the National Kidney Disease Outcomes
Quality Initiative guidelines16 as follows: stage I, eGFR
$90 mL/min/1.73 m2; stage II, 60-89 mL/min/
1.73 m2; stage III, 30-59 mL/min/1.73 m2; and stage IV,
15-30 mL/min/1.73 m2.
Renal function deterioration after EVAR was deﬁned
by >25% decrease in eGFR at any time point compared
with preoperative baseline values. Acute kidney injury was
determined by the RIFLE criteria (Risk, Injury, Failure,
Loss, and End-stage Kidney).17 The risk (“R”) of renal
dysfunction was deﬁned as increased serum creatinine
(SCr) of 1.5-fold (or decrease in baseline GFR of >25%),
injury to the kidney (“I”) as increased SCr of twofold (or
decrease in baseline GFR of >50%), failure (“F”) of kidney
function as increased SCr of threefold (or decrease in base-
line GFR of >75% or rise of 0.5 mg/dL if previous SCr of
4 mg/dl), loss (“L”) of kidney function as persistent renal
failure with need for renal replacement therapy for 4 weeks,
and end-stage (“E”) kidney disease as need for dialysis for
more than 3 months.17
Blood pressure assessment. Deﬁnition of hyperten-
sion was based on the Seventh Report of the Joint National
Committee (VII JNC) guidelines.18 Blood pressure mea-
surements were obtained from patients’ records from two
main hospitals in Rochester, Minn and 14 community-
afﬁliated facilities or from correspondences provided by
patients and their primary care providers. All postoperative
blood pressure measurements were considered throughout
follow-up with a mean of 17 blood pressure assessments
per patient (range, 5 to 51).
Kidney size, volume, and estimates of infarct size.
All patients had paired pre- and postoperative CT imaging
obtained >12 months after the operation by either
a SOMATOM Sensation 16 or 64 multidetector CT
(Siemens Solutions USA Inc, Malvern, Pa). A CTA
protocol consisted of 2-mm slice thickness, 1-mm incre-
ment, 120 KVp, and 240 mAs. Measurements of kidney
length and parenchymal changes were performed by
a single experienced 3D laboratory technician using a dedi-
cated workstation (Vitrea 2; Dell Inc, Round Rock, Tex) to
select the region of interest of the kidneys, including the
edges of the kidney parenchyma. Kidney volume was auto-
matically calculated by the workstation utilizing protocol
previously reported.19 The same volume technique was
applied to measure infarcted areas, deﬁned by areas of no or
delayed enhancement of initial hypoattenuation (“ﬂip-
ﬂop” delayed enhancement).20 Subsequently, the volume
of parenchymal infarction was subtracted from the total
kidney volume to obtain the actual area of infarction
secondary to ARA occlusion.
The diameter of each ARA was assessed using centerline-
of-ﬂow analysis (iNtuition Workﬂow Platform; TeraRecon
Inc, San Mateo, Calif), tracing multiple points inline to the
aortic lumen that rendered the aortic image straight in
order to facilitate vessel diameter measurements and the rela-
tionship between the aorta and its branches including
the distance from the ARA from the beginning of the
Table I. Demographics, clinical characteristics, and cardiovascular risk factors of 119 patients with covered, preserved,
and no accessory renal artery (ARA) during endovascular aneurysm repair (EVAR)
Group 1 (covered)
(n ¼ 42), No. (%)
Group 2 (controls)
(n ¼ 42), No. (%)
Group 3 (uncovered)
(n ¼ 35), No. (%) P value
Demographics
Age, years 74.38 6 6.63 74.43 6 6.47 75.29 6 6.36 .80
Male gender 38 (90) 38 (90) 34 (98) .46
Hypertension 32 (76) 29 (69) 26 (74) .75
Hyperlipidemia 25 (59) 14 (33) 27 (77) <.001
Coronary artery disease 24 (57) 20 (48) 25 (71) .11
Chronic obstructive pulmonary disease 14 (33) 10 (24) 16 (46) .13
Current smoking 6 (14) 7 (17) 7 (20) .80
Cerebral vascular disease 8 (19) 6 (14) 4 (11) .64
Peripheral artery occlusive disease 6 (14) 4 (9) 4 (11) .79
Prior myocardial infarction 10 (24) 12 (28) 15 (43) .18
Diabetes 8 (19) 7 (17) 5 (14) .86
Hypertension
Stage 1 (SBP 140-159; DBP 90-99 mm Hg) 9 (22) 17 (40) 13 (37) .14
Stage 2 (SBP $160; DBP $100 mm Hg) 4 (9) 3 (7) 5 (14) .58
CKD
“Normal” (>90 mL/min/1.73 m2) 5 (17) 5 (17) 3 (9) .87
Stage 2 (60-90 mL/min/1.73 m2) 17 (40) 17 (40) 21 (60) .15
Stage 3 (30-60 mL/min/1.73 m2) 18 (43) 18 (43) 11 (33) .51
GFR mL/min/1.27 m2 68 6 3 67 6 3 67 6 3 .9
CKD, Chronic kidney disease; DBP, diastolic blood pressure; GFR, glomerular ﬁltration rate; SBP, systolic blood pressure.
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follow-up visits were scheduled for 6 weeks, and 3, 6, and
12 months, and then annually with surveillance imaging
studies carried out prior to the clinical appointments.
Statistical analysis. Case matching was performed
using an SAS macro (SAS Institute, Cary, NC) to search
a 1:1 matching pair of case and control based on gender,
age (6 3 years), and estimated GFR (65 mL/min/
1.73 m2). Despite subtle differences in estimated GFR,
all matched pairs were in the same CKD stage category.
There were seven patients in the uncovered group that
we could not identify any match. Continuous variables
were reported as mean and standard deviation (SD), and
categorical variables were reported as frequency (%). They
were compared by one-way analysis of variance or Pearson
c2 test where appropriate. Survival curves were estimated
by Kaplan-Meier method and compared between cases and
controls by log-rank test. Systolic blood pressure (SBP),
diastolic blood pressure (DBP), and estimated GFR were
compared among cases and controls using analysis of
covariance. The Pearson correlation between ARA diam-
eter and percentage of renal parenchyma was obtained.
A P value less than .05 was considered statistically signiﬁ-
cant, and all statistical analyses were performed utilizing
SAS software package version 9.1.3 (SAS Institute, Cary,
NC).
RESULTS
Clinical characteristics. There were 110 (92%) male
and nine (8%) female patients with a mean age of 75 6
6.5 years included in the case-control matched analysis
(Table I). Patients in all three groups had similar demo-
graphics and cardiovascular risk factors, with the exceptionof hyperlipidemia (P < .001) in group C (Table I). Renal
function as determined by CKD stage, and mean eGFR
was similar in the three groups (Table I). Procedural data
and the types of endografts utilized are summarized in
Table II.
Early outcomes. There was one early death (1%) in an
87-year-old male patient (group C) with diabetes,
congestive heart failure (ejection fraction, 25%), and
chronic pulmonary disease who developed acute lower
extremity ischemia from distal embolization after the
EVAR. Despite thromboembolectomy, the patient died on
postoperative day 10 from worsening renal insufﬁciency
and multiorgan failure. Early morbidity was similar in all
three groups and included four patients (9%) in group A,
four (9%) in group B, and four (11%) in group C (P ¼ .9;
Table III). Early renal dysfunction occurred in 4%, 4%, and
3%, respectively. All patients with ARA who developed
renal dysfunction had occlusion of a single ARA, and all of
them were CKD stage III. The mean length of hospital stay
was similar in the three groups (2.66 0.3 days for group A,
2.7 6 0.3 days for group B, 2.4 6 0.3 days for group C;
P ¼ .8). The median follow-up for the entire cohort was
37 months (range, 6 to 105 months) and was similar in
all three groups. Patient survival at 3 years was 73% 6 9%
in group A, 65%6 9% in group B, and 78%6 8% in group C
(P ¼ .6). There was no late aneurysm-related rupture or
death.
ARAs and renal infarcts. Forty-four ARAs were iden-
tiﬁed in 42 patients in group A with an incidence of 5% of
bilateral ARAs. Intentional coverage of an ARA was
required because of anatomical location originating from
the proximal landing zone in 22 patients, aneurysm sac in
20, and the distal landing zone in two patients with ARAs
Table II. Stratiﬁcation of 119 patients with covered, preserved, and no accessory renal artery (ARA) during endovascular
aneurysm repair (EVAR) according to blood pressure and renal function
Group 1 (covered)
(n ¼ 42), No. (%)
Group 2 (controls)
(n ¼ 42), No. (%)
Group 3 (uncovered)
(n ¼ 35), No. (%) P value
Aneurysm/ARA data
AAA diameter, mm 58 6 11 56 6 10 58 6 11 .6
Distance main RA-ARA, mm 10 6 12 NA 2 6 3 .001
Type of endografts
Aneurx 21 (50) 18 (43) 16 (46)
Excluder 11 (26) 12 (29) 8 (23)
Zenith 9 (22) 9 (21) 9 (25) .9
Endologix 1 (2) 1 (2) 0 (0)
Ancure 0 (0) 2 (5) 2 (6)
Stent graft ﬁxation
Infrarenal 32 (76) 30 (71) 24 (69) .9
Suprarenal 9 (21) 9 (21) 9 (26)
Procedural data
Operative time, minutes 175 6 53 173 6 59 196 6 119 .1
Amount of contrast, mL 172 6 85 152 6 71 200 6 104 .08
AAA, Abdominal aortic aneurysm; NA, not applicable; RA, renal artery.
Table III. Early morbidity and mortality of 119 patients with preserved, covered, and no accessory renal artery (ARA)
who underwent endovascular aneurysm repair (EVAR)
Group 1 (covered)
(n ¼ 42), No. (%)
Group 2 (controls)
(n ¼ 42), No. (%)
Group 3 (uncovered)
(n ¼ 35), No. (%) P value
Overall major adverse eventsa 4 (9) 4 (9) 4 (11) .9
Cardiac
Arrhythmia 2 (5) 1 (2) 1 (3) .2
Myocardial infarctionb 0 (0) 1 (2) 1 (3) .3
Renal
Acute renal failure
Renal dysfunctionc 2 (4) 2 (4) 1 (3) .7
Need for dialysis 0 (0) 0 (0) 0 (0) NA
Local
Groin ecchymosis 3 (7) 3 (7) 1 (3) .7
Superﬁcial wound infection 0 (0) 2 (5) 0 (0) .2
Arterial pseudoaneurysm 0 (0) 0 (0) 0 (0) NA
NA, Not applicable.
aMajor adverse event including myocardial infarction, arrhythmia associated in unstable patients, stroke, renal dysfunction.
bNon-ST elevation myocardical infarction with normal electrocardiogram and troponin elevation.
cDecrease in the glomerular ﬁltration rate >25%.
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patients with ARAs originating from the proximal landing
zone, the mean distance between the ARA and the begin-
ning of the aneurysm sac was 8.7 6 8.5 mm. Right-sided
ARAs were located closer to the aneurysm sac than the
left-sided ARAs (7.2 6 8.1 mm vs 11.9 6 10 mm; P ¼ .1).
Among 35 patients with ARAs not covered by stent
grafts (group C), there were 38 ARAs identiﬁed, including
three patients (8%) with bilateral ARAs. These were
located above the main renal artery that was used as land-
mark for placement of the stent graft. The mean dis-
tance from the main renal artery to the ARA was greater
in group A compared with group C (Table II). The
average diameter of the ARA was 2.83 6 1 mm. Similar
diameters were found when the ARA originated from the
aortic neck or the aneurysm sac (3.1 6 1.1 mm vs 2.7 6
0.9 mm; P ¼ .2).Renal infarction was identiﬁed postoperatively in 28
patients (67%) in group A and in none of the patients in
groups B and C. Among patients with renal infarcts, nine
(32%) had suprarenal and 19 (68%) had infrarenal ﬁxation
devices (P < .05). The location of the renal infarcts
matched the anatomical distribution of the ARA covered
by stent graft (Fig 1). The estimated renal parenchymal
loss was 7% 6 11% of the total renal parenchyma (range,
5%-30%). There was direct correlation between ARA diam-
eter and percentage of renal parenchymal loss when ARA
was >3 mm (P ¼ .002; r ¼ .53). Fig 2 depicts long-
term follow-up CT of an infarcted kidney secondary to
ARA coverage and its respective parenchymal loss. The
estimated renal parenchymal loss was similar for patients
with CKD stage I to II (7% 6 3.5%) as compared with
those who had CKD stage III to IV (5% 6 3.4%). No
patients with uncovered ARAs had renal infarcts.
Fig 1. A, A computed tomography angiography (CTA) of a patient with a 5.8-cm infrarenal abdominal aortic
aneurysm (AAA) is depicted showing an area supplied by an accessory renal artery (ARA) with correspondent perfusion
defect. B, Three months from endovascular aneurysm repair (EVAR), the same malperfused area related to the
occluded ARA remains unchanged in size. C, Preoperative CT scan showing a 6.2-cm aneurysm with well-perfused
kidneys. D, At 2-month follow-up, a CTA demonstrated decreased perfusion to both upper poles. The right kidney
parenchyma infarcted area is more noticeable than the left. Note that the aneurysm sac has shrunk, and there is no
evidence of any endoleak. An exact correlation between ARA and its supplied kidney parenchyma was conﬁrmed by
CTA in both cases.
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ative hypertension was reported in 11 patients in group A,
20 in group B, and 18 in group C (Table I). The number
of medications per patient was also similar in all three
groups. Preoperative blood pressure measurements and
changes in blood pressure during follow-up intervals are
summarized in Fig 3. The overall changes in the SBP,
DBP, and mean arterial pressure in all three groups
throughout 3 years of follow-up were not signiﬁcant.
Among CKD stage III to IV patients, there was no
difference in blood pressure variations at 3- (SBP, P ¼ .3;
DBP, P ¼ .5), 6- (SBP, P ¼ .7; DBP, P ¼ .8), and 12-
month follow-up (SBP, P ¼ .4; DBP, P ¼ .5).
Changes in renal function. Changes in renal func-
tion as estimated by serum Cr and eGFR were similar
in all three groups (Fig 4). Patients with severe
pre-existing renal dysfunction (CKD III or IV) had similar
variation in serum Cr and eGFR (Fig 5) as compared with
those who had better preoperative renal function (CKD
I or II).
The presence and extent of kidney infarction did not
correlate with changes in renal function, independent of
the degree of preoperative renal dysfunction. There was
no acute renal failure event after ARA occlusion based on
the RIFLE criteria, regardless of the amount of contrast,type of device ﬁxation (eg, suprarenal), diabetes, or CKD
stage. However, risk of acute renal failure deﬁned as an
increase in SCr between 1.5- and 2-fold or a decrease in
GFR between 25% and 50% was found in one, three, and
two patients in groups A, B, and C, respectively.
Endoleak and changes in sac diameter. Forty (33%)
patients had endoleak identiﬁed by CTA. These included
seven (6%) type I, 37 (31%) type II, and one (0.8%) type
IV. No type III endoleak was found. Of the 37 type II
endoleaks, six had a patent inferior mesenteric artery in
addition to lumbar arteries, and three had patent ARAs.
These three patients had ARAs of 3 to 5 mm in diameter,
which originated from the aneurysm sac and provided
outﬂow for a type II endoleak. All the three patients had
aneurysm sac enlargement. Two patients were treated by
coil embolization of the inferior mesenteric artery and
ARA via a translumbar approach with microcatheters as
shown in Fig 6. The third patient was treated by trans-
lumbar embolization using cyanoacrylate and ethiodol.
There was no recurrence of type II endoleak related to
ARA. None of the 42 patients with ARAs originating from
the aneurysm neck developed an endoleak.
There were 14 patients with type II endoleak in
group A. Of these, three (21%) had endoleaks that origi-
nated from a lumbar artery with main outﬂow via a large
Fig 2. A, Preoperative computed tomography (CT) scan shows a patent accessory renal artery (ARA) supplying the left
upper pole of the kidney. B, Two months later, the same area is infarcted; no loss of parenchyma mass. C, After 4 years,
the right upper pole parenchymal mass is decreased in size. D, At 7-year follow-up, a CT scan demonstrated
a progressive loss of parenchymal mass despite stable estimated glomerular ﬁltration rate (eGFR) since the procedure.
Fig 3. Variation in systemic blood pressure of patients with
covered or preserved accessory renal artery (ARA) and with no
ARA following endovascular aneurysm repair (EVAR). DBP,
Diastolic blood pressure; MAP, mean arterial pressure; SBP,
systolic blood pressure.
Fig 4. Postoperative renal function in patients with preserved,
covered, and no accessory renal artery (ARA) after endovascular
aneurysm repair (EVAR). GFR, Glomerular ﬁltration rate.
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Nine patients required reintervention for endoleak,
including seven with type II and two with type I. Treat-
ment of type II endoleak was embolization, using coils in
ﬁve and coils combined with liquid agent in two. One
patient who had a symptomatic aneurysm had the endog-
raft successfully explanted. Two patients with type Ia endo-
leak were treated by placement of a proximal aortic cuff.
Aneurysm sac was stable in 56 (47%), decreased in 43
(36%) patients, and enlarged in four patients. Freedom
from any endoleak is depicted in Fig 7. Freedom from rein-
tervention at 2 years was similar in group A (64%), B (80%),
and C (96%; P ¼ .09).
DISCUSSION
In this case-control study, EVAR with ARA coverage
carried no negative impact on renal function or blood pres-
sure management, even when applied to patients with
more advanced stages of CKD. Kidney infarction occurred
in 67% of the patients who had an ARA covered and in
none of the patients who underwent EVAR with totalkidney preservation. The estimated volume of the kidney
infarct and its location correlated with the expected area
of kidney parenchyma perfused by the ARA, but the
ﬁnding that one-third of the patients with ARA covered
by the stent graft do not have any evidence of in-
farction indicates that other retroperitoneal or ureteral
branches provide collateral ﬂow to the kidney. Our data
are consistent with prior reports8-12 but add to the litera-
ture a more critical analysis of clinical, laboratory, and
anatomical outcomes with a control group and longer
follow-up.8-12
Endovascular repair has the disadvantage of not being
able to incorporate small aortic branches such as ARAs.
Although fenestrated endografts have been increasingly
utilized to incorporate visceral arteries in patients with
complex anatomy, these devices have limited applicability
in patients with small vessels (<4 mm), early bifurcations
(<12 mm), or in those with visceral arteries that are located
in close proximity to each other (<2 clock hours).23,24 The
use of fenestrations and branches to incorporate ARAs is
therefore limited, albeit possible. Although small balloon-
expandable covered stents are available for investigational
use in the coronary arteries, access to these stents is limited,
Fig 5. Subset analysis of estimated glomerular ﬁltration rate
(eGFR) variation in chronic kidney disease (CKD) class III to IV
patients who had accessory renal artery (ARA) occlusion or
preservation after endovascular aneurysm repair (EVAR) along
with those patients with no ARA.
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a concern.23 Current guidelines for fenestrated endografts
recommend vessel diameter >4 mm, with alignment of
fenestrations using >5-mm balloon-expandable or self-
expandable stent grafts.
Preservation of renal artery patency during EVAR is of
critical importance for several reasons. Decline in renal
function has been shown to increase mortality rates.25
Although there is a modest decline in renal function after
EVAR (1 mL/min/1.73 m2 per year), signiﬁcant deterio-
ration in renal function has been associated with inadver-
tent renal artery occlusion, renal artery complications
(stenosis, plaque dislodgement, or dissection), and aneu-
rysm complexity.25 In addition, endovascular instrumenta-
tion carries a risk of atheroembolization, particularly in
those patients with complex aneurysms and thrombus
involving the renal arteries or in those who need adjunctive
renal artery stenting. Implantation of fenestrated endog-
rafts, which require placement of renal artery stents, can
also be technically challenging and is associated with poten-
tially higher rates of renal artery dissection or perforations
compared with renal artery stent placement performed
for occlusive disease.23,24,26,27
Reimplantation of ARAs has been advocated to
preserve kidney function mainly in patients with pre-
existent CKD.6 In this subset of patients, long-term impli-
cations of ARA coverage and its consequences have been
poorly described. Prior reports have several limitations,
including lack of classiﬁcation of CKD, no information
on changes in blood pressure measurements, or objective
quantiﬁcation of kidney infarct volume.8 Most importantly,
none of these studies has compared outcomes with
a control group of patients with and without ARA under-
going EVAR with total kidney preservation. A small
prospective series by Dzieciuchowicz and colleagues
demonstrated that kidney function was not affected by
ARA coverage, but the study included only six patients,none of whom had CKD stage >II, with follow-up of
only 3 months.28 Greenberg and colleagues have also
studied the coverage of ARA during EVAR using eGFR
and its association with the amount of infarcted renal
mass compared with patients with uncovered ARA, but
with a shorter mean follow-up of 27 months. In that
report, 45 ARAs were covered in 40 patients with no
changes in blood pressure regimen or renal function.
Along with the published data, we also demonstrated
that intentional coverage of ARAs does not signiﬁcantly
impair renal function within the ﬁrst 3 years after EVAR,
even when applied to patients with advanced stages of
CKD. In fact, patients who underwent ARA coverage
had nearly identical eGFR and blood pressure measure-
ments at any follow-up interval as compared with those
who had total kidney preservation.8-12 Aquino and associ-
ates reported on 37 patients who had intentional coverage
of 26 ARAs.8 Despite a rate of kidney infarction of 21%,
transient elevation of serum creatinine was not signif-
icant, and only one patient with a baseline creatinine level
of 1.8 mg/dL required temporary dialysis.8 A limitation
of that report was lack of analysis of changes in eGFR.
Our study analyzed the impact of ARA occlusion in a subset
of patients with CKD stage III or IV, showing no changes
in renal function compared with those patients who had
normal renal function or earlier stages of CKD. Our ﬁnd-
ings are consistent with a recent report of 40 patients by
Greenberg and colleagues, who also indicated that
coverage of ARAs in patients with eGFR <60 mL/hr
resulted in no signiﬁcant change in renal function.12
The use of different CT scanners (16- vs 64-slice multi-
detectors) does not affect resolution or the ability to diag-
nose kidney infarction, which is dependent upon slice
thickness. This study did not determine the correlation of
kidney infarction and its effect on blood pressure and renal
function long term. It is likely that the absence of kidney
infarct on CT after occlusion of an ARA is due to other
retroperitoneal (ureteral) collaterals into ARAs. Other
possible explanations include the small size of infarct that
is not detected by CT using the current protocol.
Renal ischemia is a known factor associated with hyper-
tension. In this study, management of blood pressure
was also not affected by ARA coverage, both in patients
with normal renal function, or early or advanced stages
of CKD. There were also no changes in the type or number
of antihypertensive medications, suggesting that ARA
coverage does not affect blood pressure management.
This is consistent with the report by the Stanford group.12
The implication of ARAs in the origin of type II endo-
leaks is an important ﬁnding of this study. Retrograde
endoleaks via the lumbar arteries or the inferior mesenteric
artery are often a complex network of inﬂow and outﬂow
arteries, resembling the physiology of arteriovenous mal-
formations. Type II endoleaks are usually managed conser-
vatively, but remain the main indication for secondary
interventions in patients who have aneurysm sac enlarge-
ment after EVAR. A patent ARA originating from the
aneurysm sac may provide outﬂow for a type II endoleak.
Fig 6. A 76-year-old male who underwent endovascular aneurysm repair (EVAR) for a 5.9-cm infrarenal aortic
aneurysm was found to have a 6-mm sac enlargement detected in a 3-month follow-up computed tomography
angiography (CTA). A, A type II endoleak caused by a patent accessory renal artery (ARA) and inferior mesenteric
artery (IMA) is demonstrated in the three-dimensional reconstruction image. B, Selective catheterization of the ARA
via the translumbar approach is carried out with successful coil embolization. C, Subsequently, IMA coil embolization is
also performed with resolution of the type II endoleak.
Fig 7. Kaplan-Meier curve depicting 5-year survival free from any
endoleak in patients with no accessory renal artery (ARA) who
underwent endovascular aneurysm repair (EVAR) and in those
with ARA occlusion or preservation (standard error $10% starts
at the arrows).
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leaks from a large (>3 mm) patent ARA arising from the
aneurysm sac. Reintervention in these patients required
coil embolization of the nidus of endoleak and the ARA
outﬂow. Greenberg and associates recommended that
ARAs >3 mm must be embolized preoperatively. None
of those 40 patients who had ARA coverage developed
type II endoleak.12 Nonetheless, embolization can be tech-
nically difﬁcult if the ARA originates from a large aneurysm
sac or in areas with large amounts of thrombus. In these
cases, excessive catheter manipulations may lead to embolic
complications. We currently recommend that embolization
should be considered in those patients with large ARAs
that originate from the aneurysm sac, but caution thatthis procedure can lead to complications if the ARA is of
difﬁcult access. For those ARAs that originate from the
sealing zone and that are covered by the endograft fabric,
embolization is not necessary.
This study is novel because it compares outcomes in
patients with covered ARAs with control groups who had
total kidney preservation matched for age, gender, hyper-
tension, preoperative eGFR, and CKD stages. Anatomical
data in the size of renal infarct coupled with analysis of
ARA diameter and its correlation with endoleak, clinical
and laboratory data using eGFR and CKD stage system,
and the outcomes described using a validated renal failure
grading system (ie, RIFLE criteria) were provided. Our
ﬁndings are consistent with other reports, demonstrating
no signiﬁcant deterioration of renal function and changes
in blood pressure or antihypertensive medications, even
on patients who developed kidney infarcts and in those
with pre-existing CKD. Limitations of our study include
its retrospective design, relative small number of patients,
and follow-up of 37 months, which may be insufﬁcient
to demonstrate late changes in renal function based on
CKD stage. We have not observed adverse effects of
ARA occlusion in patients with advanced stages of CKD
but acknowledge that this study has excluded patients
with solitary kidney, those with stage V CKD, and has
included a relatively small number of patients with stage
IV CKD. Surveillance of long-term data assessing the
impact of ARA occlusion after EVAR is still warranted.
CONCLUSIONS
Our study conﬁrms that intentional occlusion of ARAs
during EVAR is safe and does not carry a signiﬁcant impact
on blood pressure and renal function at an average follow-
up of 37 months. Patients with CKD stages III or IV also
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 6 Malgor et al 1475did not have signiﬁcant changes in blood pressure and
kidney function. Preoperative embolization should be
considered in patients with ARA >3 mm arising from the
aneurysm sac, provided that this can be performed with
a low risk of embolic complications. Long-term prospective
data from ARA occlusion after EVAR are still warranted.
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